162 related articles for article (PubMed ID: 34714596)
1. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
[TBL] [Abstract][Full Text] [Related]
2. Metabolic studies of hypoxia-inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control.
Philip M; Mathew B; Karatt TK; Perwad Z; Subhahar MB; Karakka Kal AK
Drug Test Anal; 2021 Apr; 13(4):794-816. PubMed ID: 33458935
[TBL] [Abstract][Full Text] [Related]
3. Metabolic study of hypoxia-inducible factor stabilizers BAY 87-2243, MK-8617, and PT-2385 in equine liver microsomes for doping control.
Philip M; Karakka Kal AK; Mathew B; Subhahar MB; Karatt TK; Perwad Z
Drug Test Anal; 2022 Oct; 14(10):1703-1723. PubMed ID: 35853151
[TBL] [Abstract][Full Text] [Related]
4. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
[TBL] [Abstract][Full Text] [Related]
5. UPLC-MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine.
Mazzarino M; Perretti I; Stacchini C; Comunità F; de la Torre X; Botrè F
J Anal Toxicol; 2021 Feb; 45(2):184-194. PubMed ID: 32435795
[TBL] [Abstract][Full Text] [Related]
6. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.
Sackeyfio A; Lopes RD; Kovesdy CP; Cases A; Mallett SA; Ballew N; Keeley TJ; Garcia-Horton V; Ayyagari R; Camejo RR; Johansen KL; Sutton AJ; Dasgupta I
Clin Kidney J; 2024 Jan; 17(1):sfad298. PubMed ID: 38250252
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor.
Kokado Y; Kawai K; Nanjo T; Kinoshita S; Kondo K
Clin Ther; 2021 Aug; 43(8):1408-1418.e5. PubMed ID: 34511184
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Sato F; Kuroda T; Yamada M; Leung GN
Curr Drug Metab; 2022; 23(10):850-865. PubMed ID: 36017833
[TBL] [Abstract][Full Text] [Related]
10. Daprodustat: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(14):1491-1497. PubMed ID: 32880805
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
[TBL] [Abstract][Full Text] [Related]
12. Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Chavan A; Burke L; Sawant R; Navarro-Gonzales P; Vargo D; Paulson SK
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):950-958. PubMed ID: 33661566
[TBL] [Abstract][Full Text] [Related]
13. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
Imai E; Imai A
Intern Med; 2023 Nov; ():. PubMed ID: 37926547
[TBL] [Abstract][Full Text] [Related]
14. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
[TBL] [Abstract][Full Text] [Related]
15. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
16. Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice.
Nishide S; Uchida J; Matsunaga S; Tokudome K; Yamaguchi T; Kabei K; Moriya T; Miura K; Nakatani T; Tomita S
J Pharmacol Sci; 2020 Jun; 143(2):122-126. PubMed ID: 32199747
[TBL] [Abstract][Full Text] [Related]
17. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia.
Imai E; Imai A
Clin Exp Nephrol; 2024 May; ():. PubMed ID: 38767688
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
19. Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells.
Zielniok K; Burdzinska A; Kaleta B; Zagozdzon R; Paczek L
Cells; 2020 Nov; 9(11):. PubMed ID: 33139632
[TBL] [Abstract][Full Text] [Related]
20.
Bi YA; Jordan S; King-Ahmad A; West MA; Yamaguchi E; Ryu S; Mathialagan S; Tess DA; Varma MVS
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38388380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
